AIM
CRL icon

Alambic Investment Management’s Charles River Laboratories CRL Stock Holding History

Alambic Investment Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-4,715
Closed -$509K – 469
2017
Q3 		$509K Buy
4,715
+1,240
+36% +$127K 0.06% 345
2017
Q2 		$351K Sell
3,475
-330
-9% -$30.4K 0.04% 433
2017
Q1 		$342K Buy
3,805
+445
+13% +$37.8K 0.04% 479
2016
Q4 		$256K Buy
+3,360
New +$255K 0.05% 453

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Alambic Investment Management's CRL Position: Q4 2017 in Review

Alambic Investment Management sold out of Charles River Laboratories (CRL) in Q4 2017, closing a stake of 4,715 shares — an estimated $509K sold.

Alambic Investment Management first reported a position in CRL in Q4 2016 and held it in 4 quarters. The position peaked at $509K in Q3 2017. 339 funds tracked by Wall St. Rank hold CRL as of Q4 2017.

  • Alambic Investment Management reported no remaining Charles River Laboratories position as of Q4 2017 after selling out during the quarter.
  • Alambic Investment Management sold 4,715 Charles River Laboratories shares in Q4 2017, an estimated $509K.
  • Alambic Investment Management first reported a position in Charles River Laboratories in Q4 2016 and held it in 4 quarters.
  • Alambic Investment Management's Charles River Laboratories position peaked at $509K in Q3 2017.
  • 339 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2017.

Based on Alambic Investment Management's 13F filing for Q4 2017, filed 2 Feb 2018.